Treatment of granulomatosis with polyangiitis (Wegener’s)

References

• Mohammad AJ, Jacobsson LT, Westman KW, et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009;48:1560-5
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Jacobsson LT, Mahr AD, et al. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007;46:1329-37
   PubMed Web of Science ®Google Scholar
• Watts RA, Mooney J, Skinner J, et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis. Rheumatology (Oxford) 2012;51:926-31
   PubMed Web of Science ®Google Scholar
• Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. Curr Opin Rheumatol 2012;24:193-200
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014;10:463-73
   PubMed Web of Science ®Google Scholar
• van Timmeren MM, Heeringa P. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol 2012;24:8-14
   Google Scholar
• Relle M, Cash H, Schommers N, et al. PR3 antibodies do not induce renal pathology in a novel PR3-humanized mouse model for Wegener’s granulomatosis. Rheumatol Int 2013;33:613-22
   PubMed Web of Science ®Google Scholar
• Henderson SR, Copley SJ, Pusey CD, et al. Prolonged B Cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine (Baltimore) 2014;93:e229
   Google Scholar
• Jennette JC, Falk RJ. B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol 2014;36:327-38
   Google Scholar
• Lepse N, Abdulahad WH, Rutgers A, et al. Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission. Rheumatology (Oxford) 2014;53:1683-92
   PubMed Web of Science ®Google Scholar
• Thiel J, Salzer U, Hassler F, et al. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity 2013;46:429-38
   PubMed Web of Science ®Google Scholar
• Pendergraft WF3rd, Pressler BM, Jennette JC, et al. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med (Berl) 2005;83:12-25
   PubMed Web of Science ®Google Scholar
• Brogan PA, Shah V, Brachet C, et al. Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum 2004;50:927-36
   PubMed Web of Science ®Google Scholar
• Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Ballanti E, Triggianese P, Perricone R. Vasculitides and the complement system: a comprehensive review. Clin Rev Allergy Immunol 2014. [Epub ahead of print]
   Google Scholar
• Schonermarck U, Csernok E, Gross WL. Pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis: challenges and solutions 2014. Nephrol Dial Transplant 2014. [Epub ahead of print]
   Google Scholar
• Abdulahad WH, Stegeman CA, van der Geld YM, et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2007;56:2080-91
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther 2011;13:236
   PubMed Web of Science ®Google Scholar
• Abdulahad WH, Lepse N, Stegeman CA, et al. Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA). Arthritis Res Ther 2013;15:R70
   Google Scholar
• Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis in remission. Arthritis Rheum 2008;58:2196-205
   PubMed Web of Science ®Google Scholar
• Free ME, Bunch DO, McGregor JA, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum 2013;65:1922-33
   PubMed Web of Science ®Google Scholar
• Voswinkel J, Mueller A, Kraemer JA, et al. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006;65:859-64
   PubMed Web of Science ®Google Scholar
• Peikert T, Finkielman JD, Hummel AM, et al. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum 2008;58:1546-51
   PubMed Web of Science ®Google Scholar
• Wiesner O, Russell KA, Lee AS, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004;50:2954-65
   PubMed Web of Science ®Google Scholar
• Kain R, Tadema H, McKinney EF, et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012;23:556-66
   PubMed Web of Science ®Google Scholar
• Roth AJ, Brown MC, Smith RN, et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012;23:545-55
   PubMed Web of Science ®Google Scholar
• Regent A, Lofek S, Dib H, et al. Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: a proteomic approach. Clin Immunol 2014;153:123-35
   PubMed Web of Science ®Google Scholar
• Holle JU, Gross WL, Latza U, et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011;63:257-66
   PubMed Web of Science ®Google Scholar
• Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011;70:488-94
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014;371:1771-80
   PubMed Web of Science ®Google Scholar
• Basu N, McClean A, Harper L, et al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford) 2014;53:953-6
   Google Scholar
• Abdou NI, Kullman GJ, Hoffman GS, et al. Wegener’s granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. J Rheumatol 2002;29:309-16
   PubMedGoogle Scholar
• McGregor JG, Hogan SL, Hu Y, et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012;7:240-7
   PubMed Web of Science ®Google Scholar
• Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010;62:1166-73
   PubMed Web of Science ®Google Scholar
• The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach. Available from: https://clinicaltrials.gov/ct2/show/NCT01933724
   Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008;359:2790-803
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997;40:2187-98
   PubMed Web of Science ®Google Scholar
• Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44
   PubMedGoogle Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80
   PubMed Web of Science ®Google Scholar
• Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012;71:955-60
   PubMed Web of Science ®Google Scholar
• Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44
   PubMed Web of Science ®Google Scholar
• Walsh M, Faurschou M, Berden A, et al. Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2014;9:1571-6
   PubMed Web of Science ®Google Scholar
• Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum 2010;62:9-21
   PubMed Web of Science ®Google Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5
   PubMed Web of Science ®Google Scholar
• Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011;63:1435-45
   Google Scholar
• Mahr A, Heijl C, Le Guenno G, Faurschou M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol 2013;27:45-56
   PubMedGoogle Scholar
• Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20
   PubMed Web of Science ®Google Scholar
• Kallenberg CG. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? Curr Opin Rheumatol 2014;26:292-8
   Google Scholar
• Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-400
   PubMed Web of Science ®Google Scholar
• Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009;60:2156-68
   PubMed Web of Science ®Google Scholar
• Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27
   PubMed Web of Science ®Google Scholar
• Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013;42:1317-30
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Carruthers D, Chakravarty K, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 2014;53(12):2306-9
   PubMed Web of Science ®Google Scholar
• Clain JM, Cartin-Ceba R, Fervenza FC, Specks U. Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis 2014;6:58-74
   Google Scholar
• Abdulkader R, Dharmapalaiah C, Rose G, et al. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 2014;41:858-61
   PubMed Web of Science ®Google Scholar
• Besada E, Koldingsnes W, Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 2012;105:545-50
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Molloy E, Berger J. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol 2014. [Epub ahead of print]
   Google Scholar
• Sanders JS, Slot MC, Stegeman CA. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:2072-3; author reply -3
   Google Scholar
• Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis. Rheumatology (Oxford) 2007;46:1087-91
   PubMed Web of Science ®Google Scholar
• Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010;304:2381-8
   PubMed Web of Science ®Google Scholar
• Smith RM, Jones RB, Guerry MJ, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:3760-9
   PubMed Web of Science ®Google Scholar
• Roubaud-Baudron C, Pagnoux C, Meaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012;39:125-30
   PubMed Web of Science ®Google Scholar
• Rituximab Vasculitis Maintenance Study (RITAZAREM). Available from: https://clinicaltrials.gov/ct2/show/NCT01697267
   Google Scholar
• Azar L, Springer J, Langford CA, Hoffman GS. Rituximab with or without a conventional maintenance agent in relapsing granulomatosis with polyangiitis: A retrospective single-center study. Arthritis Rheumatol 2014;66(10):2862-70
   PubMed Web of Science ®Google Scholar
• Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2014;66:3151-9
   PubMed Web of Science ®Google Scholar
• Springer J, Nutter B, Langford CA, et al. Granulomatosis with polyangiitis (Wegener’s): impact of maintenance therapy duration. Medicine (Baltimore) 2014;93:82-90
   PubMed Web of Science ®Google Scholar
• Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008;58:2908-18
   PubMed Web of Science ®Google Scholar
• Walsh M, Flossmann O, Berden A, et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542-8
   PubMed Web of Science ®Google Scholar
• Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis - a meta-analysis. Rheumatology (Oxford) 2012;51:100-9
   PubMed Web of Science ®Google Scholar
• Terrier B, Saadoun D, Sene D, et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009;68:1564-71
   PubMed Web of Science ®Google Scholar
• Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20
   PubMed Web of Science ®Google Scholar
• Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-17
   PubMed Web of Science ®Google Scholar
• DeRemee RA. The treatment of Wegener’s granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum 1988;31:1068-74
   PubMed Web of Science ®Google Scholar
• de Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9
   PubMed Web of Science ®Google Scholar
• Langford CA, Monach PA, Specks U, et al. An open-label trial of abatacept (CTLA4-Ig) in non-severe relapsing granulomatosis with polyangiitis (Wegener’s). Ann Rheum Dis 2014;73:1376-9
   PubMed Web of Science ®Google Scholar
• Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s). Available from: https://clinicaltrials.gov/ct2/show/NCT02108860
   Google Scholar
• Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013;42:1317-30
   PubMed Web of Science ®Google Scholar
• Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008;58:308-17
   PubMed Web of Science ®Google Scholar
• Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9
   PubMed Web of Science ®Google Scholar
• Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8
   PubMed Web of Science ®Google Scholar
• Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS). Available from: https://clinicaltrials.gov/ct2/show/NCT00987389
   Google Scholar
• Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008;67:1343-6
   PubMed Web of Science ®Google Scholar
• Silva F, Seo P, Schroeder DR, et al. Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener’s): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011;63:2495-503
   PubMed Web of Science ®Google Scholar
• WGET. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 2005;352:351-61
   PubMed Web of Science ®Google Scholar
• Flossmann O, Jayne DR. Long-term treatment of relapsing Wegener’s granulomatosis with 15-deoxyspergualin. Rheumatology (Oxford) 2010;49:556-62
   PubMed Web of Science ®Google Scholar
• Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008;67:1322-7
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Horita Y, Tadokoro M, et al. Mizoribine induces remission of relapsed ANCA-associated renal vasculitis. Nephrol Dial Transplant 2006;21:1087-8
   PubMedGoogle Scholar
• Belimumab in Remission of VASculitis (BREVAS). Available from: https://clinicaltrials.gov/ct2/show/NCT01663623
   Google Scholar
• A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis. Available from: https://clinicaltrials.gov/ct2/show/NCT01363388
   Google Scholar
• Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis. Available from: https://clinicaltrials.gov/ct2/show/NCT02222155
   Google Scholar